![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Ent. | LSE:HCEG | London | Ordinary Share | GB00B6030H73 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:6643W Healthcare Enterprise Group PLC 18 March 2004 Healthcare Enterprise Group PLC Ebiox Cleaning Wipes NHS distribution agreement Healthcare Enterprise Group PLC (HCEG), the healthcare products and services company, announces an exchange of contracts with the NHS Purchasing and Supply Agency, resulting in Ebiox cleaning wipes being made available to the NHS. The contract awarded to Ebiox's UK distributors Vernon-Carus, will result in the cleaning wipes called Azowipe Active, being made available to all NHS hospitals via the NHS Logistics catalogue. The duration of the contract is over three years between April 2004 and October 2007. The NHS uses significant quantities of sterile wipes throughout its hospitals and alcohol wipes currently dominate this sector. Vernon-Carus was awarded this contract for Ebiox specifically because it does not contain alcohol with its associated disadvantages. Vernon-Carus expects that the superior properties of Ebiox will lead to a rapid adoption of these non-alcoholic wipes within the NHS. The fight against hospital acquired infections, MRSA in particular, has lead to the introduction of various measures to improve hospital hygiene. The use of cleaning wipes by both infection control service professionals and general nursing professionals, is growing and are estimated to account for #4 million of NHS expenditure per year. Ebiox wipes have been independently tested against a wide range of organisms including MRSA and results demonstrate effectiveness in eradicating bacteria. Ebiox Healthcare Enterprise Group has a 49% shareholding in Ebiox with options to acquire the outstanding shares. Ebiox produces a range of patented cleansing and decontamination products, which are designed to penetrate and remove the bacterial biofilm that harbours pathogens such as prions, bacteria and viruses. Ebiox cleans surgical instruments and surfaces to molecular level - achieving a 6-log reduction in contamination levels. Ebiox hand products have a reputation for cleansing without drying or irritating the skin, unlike alcohol-based products, which cause sore, dry hands, and therefore tend to disincentivise hospital staff from adhering to hand hygiene protocols. As well as the current range of products, which are now being marketed in the UK and will shortly be introduced to the US market, Ebiox had a range of exciting product innovations in development. These will assist in the control of MRSA and SARS. The company also has products for the decontamination of dental aspiration lines, hand disinfection products and retail disinfectant wipes. Ebiox has a user-friendly alcohol free product range which is non harmful to all surfaces. Stuart Bruck, Chairman, Healthcare Enterprise Group PLC, commented: "This represents another important step in the rollout of the Ebiox range of products. The Ebiox instrument sterilisation product is already in use in over 20 UK hospitals and the recent approval by the US Environment Protection Agency paves the way for our planned expansion of Ebiox into the USA, the world's largest healthcare market. "Moreover, NHS laboratory test results, earlier this month, will catalyse plans to introduce Ebiox's hand cleansing product into hospitals, unclean hands being a key contributor to the spread of infection from one patient to the next." 18 March 2004 Enquiries: Healthcare Enterprise Group PLC 020 7659 6157 Stuart Bruck Chairman Dr Gordon Wood CEO Products & Distribution Division College Hill 020 7457 2020 Nicholas Nelson Corinna Dorward Note to editors Healthcare Enterprise Group PLC A healthcare products and services company operating via two synergistic divisions: * HCEG Products and Distribution division provides a wide range of healthcare products and services * HCEG Advisory and Healthcare Services division provides services to healthcare businesses HCEG is listed on the UK AIM stock market with its head office in London and subsidiary offices in Manchester, Liverpool, Germany and the USA. HCEG is a business engaged in medical product distribution, occupational health and medical consultancy markets. These businesses underpin a range of innovative medical devices, which will be introduced to the market via HCEG's own distribution network on a world-wide basis. This information is provided by RNS The company news service from the London Stock Exchange END AGREAXDPFASLEEE
1 Year Healthcare Enterprise Chart |
1 Month Healthcare Enterprise Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions